Comparative pharmacological and immunochemical studies were conducted on a-bungarotoxin binding sites from rat brain or muscle, Torpedo electric tissue, or the TE671 or PC12 clonal cell lines. Characteristic distinctions were observed in the pharmacological profile of drugs competing for toxin binding to different tissues. Differences also were found in the proportion of toxin binding sites (membrane-bound or detergent-solubilized) that are immunologically reactive with either monoclonal antibodies directed against nicotinic acetylcholine receptors from the electric organ of Torpedo or polyclonal antisera raised against nicotinic receptors from the electric organ of Electrophorus. These results suggest that toxin binding sites are structurally heterogeneous. Structural heterogeneity of nicotinic acetylcholine receptors, neurotoxin binding sites, or both, may contribute to the manifestation of nicotinic receptor functional heterogeneity and may explain the apparent discrepancy at some sites between toxin binding activity and toxin functional potency.
In vertebrate muscle and in the electric organ of electric fish, binding properties of curaremimetic neurotoxins are consonant with the manifestation of toxin-mediated blockade of nicotinic acetylcholine receptor (nAcChoR) function (1) (2) (3) . Curaremimetic neurotoxin binding has been used as a criterion for the identification of nAcChoR-like molecules in neuronal tissues (4) (5) (6) . While toxin binding sites exist in the autonomic and central nervous systems, antagonistic potency of toxins has not been demonstrated at all nicotinic cholinoceptive loci (see refs. [4] [5] [6] . For example, a-bungarotoxin (Bgt) has been reported to bind to PC12 cells, but not to block nAcChoR function on that clonal line (7, 8) , which is a model for sympathetic neurons (9) . By contrast, Bgt binds to and antagonizes nAcChoR function on the human medulloblastoma clonal line TE671 (10) (11) (12) . These results suggest that considerable heterogeneity of functional nAcChoR exists, with respect to neurotoxin functional potency, particularly in the autonomic and central nervous systems. Such an outcome might be expected based on classical pharmacological distinctions between nicotinic cholinoceptive responses at different sites (13) (14) (15) (16) . It could be asked whether the functional heterogeneity of nAcChoR and the apparent infidelity at some sites between toxin binding properties and toxin functional potency could be attributed to structural heterogeneity of nAcChoR, toxin binding sites, or both.
In evaluation of these issues, previous studies have shown that high-affinity binding sites for Bgt in rat brain, in rat muscle, in electric tissue of Torpedo californica, and on membrane fractions prepared from PC12 and TE671 cells share a number of features (17) (18) (19) . Among these are sensitivity of toxin binding to irreversible blockade by the nAcChoR-specific alkylating agent bromoacetylcholine, which binds covalently to nAcChoRs that have been treated with the disulfide cleaving compound dithiothreitol (20) . Toxin binding sites also undergo changes in affinity for nicotinic agonists upon pretreatment with agonist (21) (22) (23) (24) or as a function of the reduction-alkylation-oxidation state of thiol residues (25, 26) . Association and dissociation rate constants for toxin binding to sites from these tissues are significantly different, but they are quite sensitive to variations in physical conditions during the assay and to solvent composition (17, 27) . Polyclonal antisera raised against purified nAcChoR from Electrophorus contain antibodies that compete with comparable efficacy for toxin binding to sites on membranes prepared from rat brain or muscle, TE671 or PC12 cells, or Torpedo electroplax (18, 19, 28) .
The present studies were undertaken to ascertain the extent of structural heterogeneity of toxin binding sites from different tissues. Pharmacological profiles for drug-mediated blockade of high-affinity toxin binding to sites in different tissues were generated, and immunological features of toxin binding sites were examined by the use of immunoprecipitation experiments with antisera and monoclonal antibodies prepared against nAcChoR from electric tissue. A preliminary report of these findings has appeared (19) .
MATERIALS AND METHODS
Tissue and Toxin Preparations. The preparation of rat brain crude mitochondrial fractions and Torpedo electroplax membranes was as described (17) . Rat muscle (upper hindlimb) particulate fractions were prepared by homogenization in 500 mM KCl/20 mM Tris-HCl, pH 7.5, and sedimentation at 30,000 x g for 10 min. The pellet was rehomogenized, filtered through cheesecloth, and subjected to sedimentation before being resuspended, sedimented, and resuspended in the appropriate assay buffer. TE671 cells and PC12 cells were maintained according to standard protocols that are described in detail elsewhere (see refs. 17 and 19) . In the preparation of membrane fractions, cells first were harvested mechanically and suspended in hypotonic medium (5 mM Tris HCl, pH 7.4) for 1 hr. Swollen cells were homogenized in a polytron, unbroken cells and other debris were collected by sedimentation at 1000 x g for 10 min, and the supernatant was subjected to sedimentation at 35,000 x g for 10 min. The resultant membrane pellet was resuspended, sedimented, and resuspended in the appropriate assay medium. Detergent-solubilized samples were derived from membranes that had been incubated with 50 mM Na2HPO4/100 mM NaCl, pH 7.4, containing 0.1% bovine serum albumin and 1% Triton X-100 and subjected to centrifugation at 40,000 x g for 10 min to precipitate insoluble material.
Abbreviations: nAcChoR, nicotinic acetylcholine receptor: Bgt, a-bungarotoxin; 125I-Bgt, 125I-labeled monoiodinated Bgt.
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The purification of Bgt and the preparation and isolation of '25I-labeled monoiodinated Bgt (125I-Bgt) have been described (17) .
Membrane bound complexes of '25I-Bgt and high-affinity toxin binding sites were prepared by reaction of membrane preparations for 1 hr with 12 I-Bgt at a final concentration of 10 nM. These samples were rinsed free of unbound toxin by two cycles of suspension in a large volume of buffer and sedimentation for 10 min at 35 ,000 x g, and were resuspended in the appropriate assay buffer. Otherwise, samples were resuspended in detergent-containing buffer for the preparation of solubilized complexes of 125I-Bgt and toxin binding sites. In every case, a control set of samples, which had undergone reaction with 125I-Bgt in the presence of a 100-fold excess of native Bgt, was carried through the entire preparation and experimental scheme.
Immunological Reagents. Two polyclonal antisera raised in rabbits against solubilized and purified nAcChoR from the electroplax of Electrophorus electricus were generously supplied by J. Patrick (Salk Institute) and are designated as anti-nAcChoR antisera 2152 and 2280 (28) (29) (30) 49) . Five sets of hybridoma supernatants that contain monoclonal antibodies raised against nAcChoR from Torpedo californica were the generous gift of D. Richman (University of Chicago) and are designated as anti-nAcChoR 56I, 60D, and 73G (31) and 249E and 383C (32) . Each antiserum and monoclonal antibody was characterized with respect to its capacity to precipitate detergent-solubilized complexes of 125I-Bgt and nAcChoR from Torpedo electric tissue under conditions of large antigen excess (see below). The quantity of toxin binding sites precipitated under these conditions was used to determine the concentration of active specific anti-nAcChoR in a given stock antiserum or hybridoma supernatant (2.4 and 11 ,M for 2152 and 2280; 550, 270, and 530 nM for 56I, 60D, and 73G; 500 nM for 249E and 383C). Aliquots of antisera and hybridoma supernatants were stored at -20°C until use. Formalin-fixed Staphylococcus aureus cells (Bethesda Research Laboratories) were diluted, sedimented at 11,000 x g for 1 min, and resuspended (100 mg/ml) in the appropriate assay buffer prior to use.
Assays. Assays involving drug competition for high-affinity '25I-Bgt binding were performed according to a described preincubation protocol (17, 26) . A theoreticaljustification for the use of this assay in determination of apparent inhibition constants for ligand-mediated blockade of '25I-Bgt binding under preequilibrium conditions is given in an earlier publication (26 set of control samples, which contained nonimmune serum or control hybridoma supernatants, were processed in parallel. In a modification of the protocol described above, membrane-bound complexes of 125I-Bgt and toxin binding sites were subjected to reaction with anti-nAcChoR or control reagents and S. aureus cells. In some experiments (e.g., with PC12 cell and rat brain membranes), in order to achieve minimal dilution of both antibody and antigen, antiserum stock was used as a vehicle to resuspend precipitated membrane pellets. Immune complexes were isolated from '25I-Bgt-labeled toxin binding sites by dilution to 1.5 ml in assay buffer, suspension in 10 ml of a 1:4 dilution (brain, Torpedo, and clonal cell membranes) or a 1:2 dilution (muscle) of isoosmolar Percoll, sedimentation for 30 min at 25,000 x g in a fixed-angle SM-24 rotor (Sorvall), and fractionation of the density gradient. In this case, unbound toxin distributes uniformly over the gradient, and material balance measurements may be made of the distribution of bound 125I-Bgt in free membranes and in antigen-containing membranes that sediment with fixed and cross-linked S. aureus cells.
RESULTS
Dose-response curves were generated to test the ability of nicotinic cholinergic drugs to inhibit high-affinity binding of Fig. 1 ) precipitation of 3% of 1251I-Bgt binding sites from rat brain was effected by either antiserum, but no significant precipitation of PC12 cell sites was detected (six experiments). These results indicate that toxin binding sites from different sources exhibit distinctive patterns of reactivity toward anti-nAcChoR antibodies.
Antigenic reactivity of unsolubilized membrane fractions that contain high-affinity 1251I-Bgt binding sites was tested for each tissue by the use of Percoll density gradients. Antigenically reactive membranes, which sediment as heavy complexes with antibody and S. aureus cells, were resolved on these gradients from unreactive membranes. Specifically bound 1251I-Bgt in immune complexes was quantitated and the data were normalized as a percentage of 1251I-Bgt bound over the entire gradient. The data were plotted in the form of Fig.  1 , and the results are summarized in Table 2 cies; '25I-Bgt binding sites from rat brain and from the human cerebellum-derived clonal line TE671 are different both pharmacologically and immunologically. Distinctions also may be made across tissues, as evidenced by differences between antigenic reactivities of 125I-Bgt binding sites from rat muscle and rat brain. The present results indicate that 125I-Bgt binding sites from the human medulloblastoma TE671 are unique, but they are more similar to sites from rat (34) (35) (36) (37) (38) , antigenic heterogeneity of toxin binding sites within a given tissue also appears to be expressed in some instances. Another example of this phenomenon is evident from the current studies that show fractional immunoprecipitation of detergent-solubilized 125I-Bgt binding sites from rat muscle or the TE671 cell line under conditions of antibody excess. This result and the aforementioned small but statistically significant immunoprecipitation of I251-Bgt binding sites from rat brain indicate that a portion of liganded toxin binding sites from these tissues is refractory to interaction with anti-nAcChoR.
The principal interpretation of the present results is that toxin binding sites express structural heterogeneity. Structural heterogeneity of physiologically relevant nAcChoRs is likely to be the source for functional heterogeneity of nicotinic cholinoceptive responses observed across species and tissues (13, 14, 39, 40) . Structural heterogeneity of toxin binding sites otherwise may account for differences in the functional expression of toxin antagonistic potency at different toxin binding nAcChoR-like sites (4) (5) (6) (7) (8) (10) (11) (12) . The manifestation of structural heterogeneity of nAcChoR from different tissues, and perhaps even within a given tissue, must be founded upon the expression of a family of nAcChoR genes, unique patterns of post-translation processing or assembly of nAcChoR gene products, or both.
This report and other literature (36, 41) 
